Loading
A phase 3 trial of Pasireotide and Somatostatin analogues in Pituitary tumours, run by Novartis Pharmaceuticals, completed.
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly is a phase 3 interventional study registered as NCT00600886 by Novartis Pharmaceuticals, with 358 participants recorded, started 2008-02-11 and reaching its primary completion in 2016-03-11. Interventions recorded: Pasireotide, Octreotide. Conditions recorded: Acromegaly.
Linked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
358 enrolled.
95% CI 24.5 to 38.7; Figures from the ClinicalTrials.gov results section (first posted 2015-01-30), not from a publication · 95% CI 13.8 to 25.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1, Overallprimary | Pasireotide LAR (Core) | 176 | 31.3% | - | 0.007 | link |
| Octreotide LAR (Core) | 182 | 19.2% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pasireotide, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pasireotide, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Somatostatin analogues (octreotide, lanreotide), Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/